Notice of Annual General Meeting/Proxy Form

Notice is hereby given that the Annual General Meeting (‘Meeting’) of Shareholders of Melodiol Global Health Limited (‘Company’) will be held by virtual meeting facility at 9.30am (WST) on Friday, 31 May 2024.

In accordance with section 110D of the Corporations Act 2001 (Cth) (as inserted by the Corporations Amendment (Meeting and documents) Act 2022 (Cth)), the Company will not be dispatching physical copies of the Notice of Meeting (‘Notice’) unless specifically requested to do so. Instead, a copy of the Notice is available on the Company’s ASX Announcement Platform at (ASX:ME1).

If you have elected to receive notices by email, a copy of your personalised proxy form will be emailed to you. If you have not elected to receive notices by email, a copy of your personalised proxy form will be posted to you, together with this letter for your convenience. Shareholders are encouraged to elect to receive all notices by email, as this will significantly reduce printing and postage costs for the Company, and helps reduce the Company’s environmental impact. You can provide your email address via your account with the Company’s share registry, Automic, which can be accessed as set out further below, or by contacting the share registry on 1300 288 664 (within Australia) (or +61 (0)2 9698 5414 (Overseas)) or by email at: [email protected].

All shareholders will be able to participate in the Meeting by:

(a) attending and voting their Shares at the Meeting to be held virtually at 9.30am (WST) on 31 May 2024;

(b) voting prior to the Meeting by lodging your proxy instructions by no later than 48 hours prior to the Meeting (by 9.30am (WST) on 29 May 2024) either:

(c) lodging questions in advance of the Meeting by emailing the questions to Winton Willesee, Company Secretary at [email protected], by no later than 24 May 2024.

Click here for the full ASX Release

This article includes content from Melodiol Global Health, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.


Leave A Reply

Your email address will not be published.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

Accessibility Tools